Lung Cancer Dispatch
Follow
Find tag "antibody-drug conjugate"
3.6K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Immunomedics Announces Objective Responses in Five Types of Solid Cancer With IMMU-132

"Immunomedics, Inc., (Nasdaq:IMMU) today reported that 71% of patients (34 of 48) with diverse metastatic solid cancers had durable disease stabilization after receiving treatments with the Company's novel investigational antibody-drug conjugate (ADC), IMMU-132. These include 7 patients (15%) with colorectal, small-cell and non-small-cell lung, esophageal, and triple-negative breast cancers showing partial responses with tumor shrinkage of 30% or more as measured by computed tomography (CT)."


Editor's note: Scientists have developed a new cancer drug called IMMU-132, which may work in a variety of cancer types. IMMU-132 is an immunotherapy, meaning it boosts a patient's own immune system to fight cancer. A clinical trial to test the drug in volunteer patients found promising results, including in non-small cell lung cancer (NSCLC) patients.

Cancer Commons's insight:

NASDAQ  |  Jun 2, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Clinical Trial of New SCLC Drug Enrolling Patients

Clinical Trial of New SCLC Drug Enrolling Patients | Lung Cancer Dispatch | Scoop.it

A clinical trial at six study sites, including Smilow Cancer Hospital at Yale-New Haven, will investigate a new treatment for small cell lung cancer (SCLC). IMGN901 (lorvotuzumab mertansine), produced by ImmunoGen, is a novel type of treatment that targets CD56, a protein that is expressed by tumors in a number of different cancers, including SCLC. Because IMGN901 specifically targets a tumor protein, the toxic drug is delivered preferentially to cancer cells and is less likely to harm healthy cells. Another drug using a similar mechanism was recently approved for breast cancer.


To find out more about the trial, call 203-200-5864.

ImmunoGen page on IMGN901: http://www.immunogen.com/pipeline/lorvotuzumab-mertansine/

Cancer Commons's insight:

New Haven Register | Mar 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

First Clinical Trial of New Cancer Drug IMGN289 Begins

A phase I clinical trial marks the start of early testing for new cancer drug IMGN289. IMGN289 is a so-called antibody-drug conjugate (ADC). ADCs combine antibodies (immune system proteins designed to bind to specific targets) with chemotherapy drugs to help steer the chemotherapy agents specifically towards tumors and spare healthy tissues. IMGN289 consists of an antibody that binds to EGFR, a protein expressed in many lung cancer tumors, connected to a cell-killing agent called DM1. The trial will study patients with non-small cell lung cancer (NSCLC) and other cancers that express high levels of EGFR. After determining the highest IMGN289 dose that can safely be administered to patients, the study will evaluate the effectiveness of the drug in different patient subgroups.

Cancer Commons's insight:

ImmunoGen, Inc. | Nov 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Pilot Study of New SCLC Drug Offers Encouragement

Preliminary trial results indicate that a new drug, IMGN901, enhances standard etoposide/carboplatin treatment in some small cell lung cancer (SCLC) patients. IMGN901 targets cells that express the protein CD56—a hallmark of nearly all SCLC tumors. ImmunoGen, Inc. will further investigate the SCLC treatment potential of IMGN901 in the large-scale NORTH trial.

Cancer Commons's insight:

equities.com | Sep 11, 2012

more...
No comment yet.